Browsing: Diabetes

In a 25-person crossover trial, ultra-rapid lispro blunted the glucose fall during exercise after basal rate reduction compared with lispro in adults with type 1 diabetes on conventional pump therapy.

In HISTORI (n=154), semaglutide 1.0 mg weekly for 30 weeks lowered fasting glucose by 0.87 mmol/L and improved insulin sensitivity in people with schizophrenia, prediabetes and obesity on antipsychotics.

In a multinational RCT (n=293), the virtual Diabetes Body Project improved eating disorder symptoms (d -0.30), diabetes distress and body image versus education control; effects were measured only 1 to 2 weeks after.

In the TIGHT trial (n=110), CGM-guided intensive management aiming for 90 to 130 mg/dL did not lower mean glucose versus standard care (170 vs 175 mg/dL; P=0.25) in non-ICU adults with type 2 diabetes.

SURMOUNT-1 at 3 years: tirzepatide lowered weight by 12.3 to 19.7% vs 1.3% on placebo, and progression to type 2 diabetes (HR 0.07) in prediabetes.

In 55 older women with type 2 diabetes, pyridoxamine 200 mg twice daily missed its primary P1NP endpoint (P=0.056) but increased femoral neck BMD and lowered HbA1c in secondary analyses.

In 131 adults aged 65 or older with type 1 diabetes and hypoglycaemia, CGM with geriatric principles cut time below 70 mg/dL by a median 2.3 points versus usual care (P<0.001) with no change in HbA1c.

In 12 adults with type 1 diabetes, adding volagidemab to dapagliflozin raised time in range to 86% (vs 78% and 70%), cut insulin dose and lowered peak ketones versus dapagliflozin alone (2.0 vs 2.4 mmol/L).

After a median 22 years, clinically diagnosed retinopathy was 8.9% with lifestyle intervention versus 7.7% with control (OR 1.15; 95% CI 0.61 to 2.21); higher cumulative HbA1c was associated with higher risk.

In SURPASS-PEDS, weekly tirzepatide lowered HbA1c by 2.28 points versus placebo at 30 weeks and also reduced BMI in youth-onset type 2 diabetes.